Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Estela Moreno-García, M.D.*¹; Verónica Rico, M.D.*¹; Laia Albiach, M.D.¹; Daiana Agüero, M.D.¹; Juan Ambrosioni, M.D., Ph.D.¹; Marta Bodro, M.D., Ph.D.¹; Celia Cardozo, M.D.¹; Mariana Chumbita, M.D.¹; Lorena De la Mora, M.D.¹; Nicole García-Pouton, M.D.¹; Carolina Garcia-Vidal, M.D., Ph.D.¹; Ana González-Cordón, M.D., Ph.D.¹; Marta Hernández-Meneses, M.D.¹; Alexy Inciarte, M.D.¹; Montse Laguno, M.D., Ph.D.¹; Lorna Leal, M.D., Ph.D.¹; Laura Linares, M.D.¹; Irene Macaya, M.D.¹; Fernanda Meira, M.D.¹; Josep Mensa, M.D.¹; Antonio Moreno, M.D.¹; Laura Morata, M.D., Ph.D.¹; Pedro Puerta-Alcalde, M.D., Ph.D.¹; Jhon Rojas, M.D., Ph.D.¹; Montse Solá¹; Berta Torres, M.D., Ph.D.¹; Manuel Torres, M.D.¹; Adrià Tomé, M.D.¹; Pedro Castro, M.D., Ph.D.²; Sara Fernández, M.D.²; Josep Maria Nicolás, M.D., Ph.D.²; Alex Almuedo-Riera, M.D.³; Jose Muñoz, M.D., Ph.D.³; Mariana Jose Fernandez-Pittol, M.D.⁴; Maria Angeles Marcos, M.D., Ph.D.⁴; Dolors Soy, M.D., Ph.D.⁵; José Antonio Martínez, M.D., Ph.D.¹; Felipe García, M.D., Ph.D.¹, and Alex Soriano, M.D., Ph.D.^{†1}.

* both authors contributed equally to this manuscript.

¹Department of Infectious Diseases, Hospital Clínic-Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

²Medical Intensive Care Unit, Hospital Clínic-Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

³ Department of International Health, ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁴Department of Microbiology, Hospital Clínic-Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

⁵Department of Pharmacology, Hospital Clínic-Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

[†]**Corresponding author:**

Alex Soriano, M.D. Ph.D.

Department of Infectious Diseases, Hospital Clínic of Barcelona.

Carrer de Villarroel 170, 08036, Barcelona, Spain

Phone +34 932 275 400; ext.2887

E-mail: asoriano@clinic.cat

Funding: There are none funding or conflicts of interest to declare.

Word count: 1953

Abstract

Background

In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one of the major burdens in the management worldwide; therefore, clinical strategies to avoid ICU admission are needed.

Objective

We aimed to describe the influence of tocilizumab on the need of transfer to ICU or death in non-critically ill patients.

Methods

A retrospective study of 171 patients with SARS-CoV-2 infection that did not qualify as requiring transfer to ICU during the first 24h after admission to a conventional ward, were included. The criteria to receive tocilizumab was radiological impairment, oxygen demand or an increasing of inflammatory parameters, however, the ultimate decision was left to the attending physician judgement. The primary outcome was the need of ICU admission or death whichever came first.

Results

77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, $P=0.005$) and need of invasive ventilation (0 vs 13.8%, $P=0.001$). In multivariable analysis, tocilizumab remained as a protective variable (OR: 0.03, CI 95%: 0.007-0.1, $P=0.0001$) of ICU admission or death.

Conclusion

Tocilizumab in the early stages of the inflammatory flare, could reduce ICU admissions and mechanical ventilation use. The mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than other reports.

Clinical implication

Our results suggest that tocilizumab administered to non-critically ill patients could reduce ICU admissions and mortality.

Capsule summary: Tocilizumab administered to non-critically ill patients with SARS-CoV-2 infection in the early stages of the inflammatory flare, could reduce an important number of ICU admissions and mechanical ventilation use.

Key words: SARS-CoV-2 infection, COVID-19, tocilizumab, IL-6 inhibition, acute respiratory distress syndrome (ARDS).

84 **Abbreviations:**

85 ALS: Advanced Life Support

86 ARDS: Acute Respiratory Distress Syndrome

87 CRP: C-Reactive Protein

88 ICU: Intensive Care Unit

89 MV: mechanical ventilation

90 PCR: Polymerase Chain Reaction

91 PS: Propensity Score

92 SD: Standard Deviation

93

Introduction

Infection by Coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan and rapidly spread around the world. SARS-CoV-2 pneumonia evolves in 2 different phases, the first one is characterized by a high viral replication and classical symptoms of a respiratory virus infection, including fever, malaise, myalgia, and cough (1). About 80% of the patients control the infection within a week but 20% of them, after the first 7-8 days, develop a severe respiratory failure fulfilling the definition of acute respiratory distress syndrome (ARDS) with many requiring intensive care management (2). During the second week, the blood tests reveal lymphopenia, and high levels of C-reactive protein (CRP), ferritin, and D-dimer values (1), all related with the activity of different cytokines (IL-1beta, IL-2, IL-6, IL-8, IL-17, IFN-gamma or TNF-alpha) (3). Therefore, the main therapeutic objective during the first week of treatment is to stop the viral replication while in the second week blocking the tissue damage induced by the cytokine storm is paramount (4).

In agreement with the immunopathogenesis, it has been proposed to treat patients during the inflammatory flare with IL-6 inhibitors (5,6). The first description included 21 patients admitted to a Chinese hospital who received tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody. In a few days, symptoms improved remarkably, 75% had lowered their oxygen intake and no patient died (7). More recently, Sciascia and colleagues, have reported the results of a single-arm multicentre study on off-label use of tocilizumab conducted in 63 Italian patients with a severe SARS-CoV-2 infection. The administration of tocilizumab within 6 first days of admission was associated with an increased likelihood of survival (HR 2.2 95% CI 1.3–6.7, $p < 0.05$) (8).

On the other hand, 21 Italian patients received siltuximab, a chimeric monoclonal antibody that binds to and blocks the effect of IL-6. The outcome showed that 33% (7/21) of patients experienced an improvement in their condition with a reduced need for ventilation, 43% (9/21) remained stable, and 24% (5/21) worsen and required intubation. However, this article is included in a repository so not yet peer reviewed (9). The main objective of the present article is to describe the putative influence of tocilizumab on the prognosis, defined as eventual need of transfer to the ICU or death, of 171 non-critically ill patients.

Methods

From February 19th to April 16th patients with respiratory symptoms and radiological evidence of pneumonia (uni or bilateral interstitial infiltrates) and those with respiratory symptoms without pneumonia but with co-morbidity (hypertension, diabetes mellitus, cancer, chronic liver diseases, chronic obstructive pulmonary disease or immunosuppression) were admitted to Hospital Clínic of Barcelona in the context of SARS-CoV-2 pandemic. Definitive diagnostic was established by a positive polymerase chain reaction (PCR) from a nasopharyngeal swab during the first two weeks of pandemic but once the prevalence of positive tests was >70%, the diagnosis was based on clinical criteria. Clinical criteria for defining a case of SARS-CoV-2 were the presence of respiratory symptoms with uni or bilateral interstitial infiltrate in the chest-X ray without evidence of other potential causes (e.g. heart failure). During the study period, 171 patients that did not qualify as requiring transfer to the ICU during the first 24h after admission to a conventional hospital ward, were included. For ARDS, the Berlin definition (10) was applied. When PaO₂ was not available, SpO₂/FiO₂ ≤ 315 suggested ARDS (including in non-ventilated patients) (11).

The standard protocol included antiviral treatment that consisted of lopinavir/ritonavir 400/100 mg BID for 7-14 days plus hydroxychloroquine 400 mg/12h on the first day, followed by 200 mg/12h for the next 4 days. From the 18th of March onwards, azithromycin 500 mg the first day and 250 mg/24h for 4 additional days was added to the regimen. In addition, a clinical trial with remdesivir was enrolling patients in our institution during the study period. All patients with risk factors for thrombosis received prophylactic doses of low molecular weight heparin (12). Intravenous methylprednisolone was recommended for patients with disease progression to ARDS. The local protocol suggested the use of tocilizumab for patients with pneumonia, progressive respiratory failure (increasing fraction of inspired oxygen) and CRP ≥ 8 mg/dL or ferritin ≥ 800 ng/mL or lymphocyte count < 800 cells/mm³. The dose was 400 mg/24h iv for patients with ≤ 75 kg and 600 mg/24h iv for those with > 75 kg with the possibility to repeat the dose every 12h up to 3 doses in case of only partial response. However, due to the lack of evidence to support its efficacy, the ultimate decision about using tocilizumab was left to the judgement of the attending physician. Patients with severe comorbidity and a life expectancy < 6 months were considered no tributary of advanced life support (ALS). The outcome variable was a composite of the need of ICU admission or death whichever came first. The last revision of medical charts was April 26th.

The Institutional Ethics Committee of the Hospital Clínic of Barcelona approved the study and due to the nature of retrospective chart review, waived the need for informed consent from individual patients (Comité Ètic d'Investigació Clínica; HCB/2020/0273).

Statistical analysis

Categorical variables were described using the absolute number and percentage and continuous variables using the mean and standard deviation (SD). Categorical variables were compared using a Chi-squared test or Fisher exact test when necessary, and means by using the Student-t test. For multivariable analysis, variables with a P -value ≤ 0.2 in the univariable analysis were subjected to further selection by using a backward logistic regression procedure. Interactions between variables were explored. In order to reduce the effect of selection bias, we estimate the propensity score (PS) to receive tocilizumab as the predicted probability from a logistic regression model using tocilizumab as the dependent variable. The PS was included in the multivariable analysis of the main outcome. The calibration of the model was assessed by means of the Hosmer-Lemeshow goodness-of-fit test. Statistical significance was defined as a two-tailed P value < 0.05 . The analysis was performed in SPSS version 23 (SPSS Inc., Chicago, IL).

Results

The cohort included 171 patients, of whom 77 received tocilizumab while staying in a conventional ward and 94 did not, with a mean (SD) age of 61.5 (12.4) and 61.4 (16) years, respectively. The proportion of males and the main comorbidities were similar between both groups (Table 1). Patients in the tocilizumab group had more frequently fever, pneumonia (interstitial infiltrate) and at day 1 they needed more often oxygen therapy. C-reactive protein levels were significantly higher in the tocilizumab group (9.7 mg/dL vs. 7.5 mg/dL, $P=0.04$) but other biological parameters were similar in both groups. During patients' stay in a conventional ward, corticosteroid therapy was more frequently administered in the tocilizumab group (50.6% vs. 27.7%, $P=0.002$). A total of 26 patients were not candidates to ALS, 10 (12.9%) in the tocilizumab group and 16

(17%) among controls. The mean (SD) time from symptoms onset to hospital admission in tocilizumab group was 6.5 (3.3) days while it was 5 (6.5) days in the control group. The outcome of both groups, with >90% of patients discharged alive or dead, showed that patients in the tocilizumab group had significantly less ICU admissions (10.3% vs. 27.6%, $P=0.005$) and less need of invasive ventilation (0 vs 13.8%, $P=0.001$) (Figure 1). The univariable analysis of our composite outcome (ICU admission or death whichever came first) showed that comorbidities (hypertension, heart diseases and lymphoma), the need of oxygen at day 1, a CRP > 16 mg/dL and the development of cardiovascular, renal or respiratory (ARDS, invasive ventilation) complications were significantly associated with the primary outcome. In contrast, tocilizumab was the only one protective variable (Table 2). In the multivariable analysis, including the PS estimate to receive tocilizumab as a potential confounder, tocilizumab remained as a strong protective variable (OR: 0.03, CI 95%: 0.007-0.1, $P=0.0001$) of ICU admission or death (Table 3).

Discussion

Monoclonal antibodies directed against key inflammatory cytokines represent a class of potential adjunctive therapies for SARS-CoV-2 infected patients. The rationale for their use is that the underlying pathophysiology of significant lung damage is caused by a cytokine storm being IL-6 one of the main drivers. Therefore, monoclonal antibodies against IL-6 or its receptor could theoretically improve clinical outcomes mainly by reducing the need of ICU admission and consequently the associated mortality. Tocilizumab, a monoclonal antibody IL-6 receptor antagonist, was administered to 77 patients admitted to a conventional ward in our hospital and the outcome was compared with 94 patients also admitted in a conventional ward during the same period of time

216 that did not receive tocilizumab. Although this study was not randomized, the
 217 characteristics of both groups did not differ in terms of demographics and comorbidities
 218 Moreover, the tocilizumab group had more severe infection (pneumonia, need of
 219 oxygen at day 1 or higher CRP). Furthermore, all the patients were evaluated during the
 220 same period of time so the same criteria for being transferred to the ICU was applied.
 221 After adjusting for potential confounders, including the PS for receiving tocilizumab,
 222 the multivariable analysis revealed that tocilizumab was an independent factor
 223 associated with a reduction in the need of ICU admission and death. The need of ICU in
 224 the tocilizumab group was almost 3 times lower (10.3% vs. 27.6%) than in controls and
 225 it was lower than the one reported in Wuhan hospitals (26%) (1,13) or more recently in
 226 New York (14%) (14). The availability of ICU beds is critical for the management of
 227 patients that develop a severe ARDS in few hours, therefore, reducing the need of ICU
 228 beds using tocilizumab impacted directly not only on the outcome of patients that
 229 received the treatment but also of those that not receiving tocilizumab or arriving too
 230 late in a critically ill condition had more chances of being admitted in the ICU. In line
 231 with this, the mortality of our cohort, including patients not candidates to ALS, was
 232 14.2% which seems lower than that showed in previous reports, regularly >20%
 233 (1,13,15). Indeed, the mortality rate of patients in the tocilizumab group was 10% that is
 234 comparable to the one recently reported with remdesivir (15) in 53 patients (13%).
 235 Although from the beginning of the pandemic tocilizumab was recommended in the
 236 general protocol, the heterogenicity of its prescription could be explained by the lack of
 237 clinical randomized trials supporting its usefulness.
 238 Our results suggest that tocilizumab should be administered in early phases of the
 239 inflammatory flare. It is reasonable to hypothesize that other strategies directed to
 240 inhibit other specific inflammatory pathways (including IL-1 with anakinra or INF-

gamma with JAK inhibitors), or a broad-spectrum inhibition with steroids with or without therapeutic strategies to reduce the pro-coagulant status, could be also effective (16-18). On the other hand, although in non-severe cases after one week from symptoms onset the viral viability is significantly reduced, there is data supporting the continuous viral replication in severe cases (19) that could be the trigger for the inflammatory flare and its maintenance. In addition, different antiviral strategies (antiviral agents, plasma from convalescent patients) have demonstrated benefit in severe patients, even >1 week after symptoms onset (15, 20-21). Accordingly, we consider that antiviral agents should be associated with immunomodulators (22), and this explains why almost 100% of our cohort received it.

In conclusion, while waiting for the definitive results from clinical trials with tocilizumab (NCT04310228, ChiCTR200002976), our findings support that the administration of tocilizumab in the early stages of the inflammatory flare, particularly before the need of ICU admission, is more convenient and could potentially avoid an important number of ICU admissions and mechanical ventilation use. Consequently, the mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than that described by others in previously published series (13,15,23). However, this is a non-randomized study and, therefore, the results should be interpreted with caution.

Acknowledgements

Hospital Clinic of Barcelona COVID-19 Research Group:

Infectious Diseases' Research Group:

Blanco JL, Mallolas J, Martínez E, Martínez M, Miró JM, Moreno A, and all the staff members.

266 Medical Intensive Care Unit:

267 Adrian Téllez, and all the staff members.

268

269 Department of International Health:

270 Daniel Camprubi Ferrer, Maria Teresa de Alba, Marc Fernandez, Elisabet Ferrer, Berta

271 Grau, Helena Marti, Magdalena Muelas, Maria Jesus Pinazo, Natalia Rodríguez,

272 Montserrat Roldan, Carme Subira, Isabel Vera, Nana Williams, Alex Almuedo-Riera,

273 Jose Muñoz, and all the staff members.

274

275 Department of Internal Medicine:

276 Aldea A, Camafort M, Calvo J, Capdevila A, Cardellach F, Carbonell I, Coloma E,

277 Foncillas A, Estruch R, Feliu M, Fernández-Solá J, Fuertes I, Gabara C, Grafia I,

278 Ladino A, López-Alfaro R, López-Soto A, Masanés F, Matas A, Navarro M, Marco-

279 Hernández J, Miguel L, Milisenda J, Moreno P, Naval J, Nicolás D, Oberoi H, Padrosa

280 J, Prieto-González S, Pellicé M, Ribot J, Rodríguez-Núñez O, Sacanella E, Seguí F,

281 Sierra C, Ugarte A, Ventosa H, Zamora-Martínez C, and all the staff members.

282

283 Department of Microbiology:

284 Almela M, Alvarez M, Bosch J, Casals C, Costa J, Cuesta G, Fidalgo B, González J,

285 Hurtado JC, Marco F, Martínez M, Mosquera M, Narvaez S, Pitart C, Rubio E, Vergara

286 A, Valls ME, Vila J, Zboromyrska Y and all the staff members.

287

288 Department of Farmacy:

289 López E, Tuset M and all the staff members.

290

291 Department of Autoimmune diseases:
292 Espigol G, Espinona G and all the staff members.
293

References

1. Zhou F, Yu T, Du R, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study. *Lancet* 2020; 395: 1054–62. DOI: 10.1016/S0140-6736(20)30566-3.
2. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020. April 6. (Epub ahead of print) DOI:10.1001/jama.2020.5394.
3. McGonagle D, Sharif K, O'Regan A, et Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmunity Reviews* 2020. April 3. (Epub ahead of print). DOI: 10.1016/j.autrev.2020.102537.
4. Siddiqi HK, Mandeep RM. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. *J Heart and Lung Transpl* 2020. DOI: 10.1016/j.healun.2020.03.012.
5. Zhang C, Wu Z, Li JW, Zhao H and Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. *Int J Antimicrob Agents* 2020. March 29. (Epub ahead of print). DOI: 10.1016/j.ijantimicag.2020.105954
6. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020. April 17. (Epub ahead of print). DOI: 10.1126/science.abb8925.
7. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. *Proc Natl Acad Sci U S A*. 2020. April 29 (Epub ahead of print). PMID: 32350134.

- 318 8. Sciascia S, Apra F, Baffa A et al. Pilot Prospective Open, Single-Arm
319 Multicentre Study on Off-Label Use of Tocilizumab in Patients With Severe
320 COVID-19. Clin Exp Rheumatol 2020. May 1. (Epub ahead of print). PMID:
321 32359035
- 322 9. Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with
323 COVID-19 pneumonia requiring ventilatory support. MedRxiv 2020.
324 DOI:10.1101/2020.04.01.20048561.
- 325 10. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT,
326 Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory
327 distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33.
328 doi: 10.1001/jama.2012.5669.
- 329 11. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA et Ware LB.
330 Comparison of the SpO₂/FIO₂ ratio and the PaO₂/FIO₂ ratio in patients with
331 acute lung injury or ARDS. Chest. 2007;132(2):410–417.
332 DOI:10.1378/chest.07-0617.
- 333 12. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or
334 Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy,
335 and Follow-up. J Am Coll Cardiol 2020. April 15. (Epub ahead of print). DOI:
336 10.1016/j.jacc.2020.04.031.
- 337 13. Wu C, Chen X, Cai Y et al. Risk Factors Associated With Acute Respiratory
338 Distress Syndrome and Death in Patients With Coronavirus Disease 2019
339 Pneumonia in Wuhan, China. JAMA Intern Med 2020. March, 13. (Epub ahead
340 of print). DOI:10.1001/jamainternmed.2020.0994.
- 341 14. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
342 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-

343 19 in the New York City Area. JAMA 2020. April 22 (Epub ahead of print).
344 DOI: 10.1001/jama.2020.6775.

345 15. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for
346 Patients with Severe Covid-19. N Engl J Med 2020. April,10. (Epub ahead of
347 print). DOI: 10.1056/NEJMoa2007016.

348 16. Cavalli G, De Luca G, Campochiaro C et al. Interleukin-1 blockade with high-
349 dose anakinra in patients with COVID-19, acute respiratory distress syndrome,
350 and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020.
351 May 7. (Epub ahead of print) DOI: 10.1016/S2665-9913(20)30127-2

352 17. Ingraham NE, Lofti-Emran S, Thielen BE et al. Immunomodulation in COVID-
353 19. Lancet Respir Med 2020. May 4. DOI: 10.1016/ S2213-2600(20)30226-5.

354 18. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-
355 inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-402. DOI:
356 10.1016/S1473-3099(20)30132-8.

357 19. Lin A, He ZB, Zhang S, Zhang JG, Zhang X, Yan WH. Early risk factors for the
358 duration of SARS-CoV-2 viral positivity in COVID-19 patients. Clin Infect Dis
359 2020. April 27. (Epub ahead of print). DOI: 10.1093/cid/ciaa490.

360 20. Shen C, Zhaoqin W, Zhao F et al. Treatment of 5 Critically Ill Patients With
361 COVID-19 With Convalescent Plasma. JAMA 2020. March, 27. (Epub ahead of
362 print). DOI: 10.1001/jama.2020.4783.

363 21. Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities
364 and Challenges. JAMA 2020. March, 27. (Epub ahead of print).
365 DOI:10.1001/jama.2020.4940.

- 366 22. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
367 Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA
368 2020. April, 13. DOI:10.1001/jama.2020.6019.
- 369 23. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults
370 Hospitalized with Severe Covid-19. N Engl J Med 2020. March, 18. (Epub
371 ahead of print) DOI:10.1056/NEJMoa2001282.
- 372

373 **Table 1. Characteristics and outcome of patients that received or did not received**
 374 **tocilizumab in a conventional ward.**

Variables	Tocilizumab group (N=77)	Control group (N=94)	P - value
Mean (SD) age in years	61.5 (12.4)	61.4 (16.0)	0.957
Age > 62 years old (%)	40 (52)	52 (55.3)	0.660
Male (%)	53 (68.8)	59 (62.7)	0.406
Comorbidities (%)			
Hypertension	35 (45.4)	43 (45.7)	0.960
Heart diseases	12 (15.5)	21 (22.3)	0.265
Chronic respiratory disease	8 (10.3)	12 (12.7)	0.630
Diabetes Mellitus	12 (15.6)	14 (15)	0.900
Mean (SD) days from symptoms onset to admission	6.5 (3.3)	5 (6.5)	0.061
Initial characteristics (%)			
Fever	86 (98.7)	80 (85)	0.002
Dyspnea	33 (43)	47 (50)	0.352
Cough	64 (83)	70 (74.5)	0.172
Normal chest x-ray at admission	3 (4)	14 (15)	0.017
Need of oxygen therapy at day 1	56 (72.7)	50 (53.8)	0.011
Positive PCR from a nasal swab	68 (88.3)	82 (87.2)	0.831
Laboratory at admission mean (SD)			
D-dimer (ng/mL) ¹	918.6 (1354.8)	1503.9 (2175.4)	0.100
Lymphocytes count (cell/mm ³)	878.9 (452.8)	910.1 (534.6)	0.686
C-Reactive protein (mg/dL) ²	9.7 (7.4)	7.5 (5.7)	0.044
Serum ferritin (ng/dL) ³	867.8 (871)	904.1 (809.9)	0.842
ARDS at any given time (%)	24 (31.1)	26 (27.6)	0.616
Treatments received (%)			
Antiviral agents ⁴	77 (100)	91(96.8)	0.164

Steroid prior ICU admission	39 (50.6)	26 (27.7)	0.002
Not candidate to ALS (%)	10 (12.9)	16 (17)	0.465
Mean (SD) days of follow up	11.2 (6.2)	14.7 (10.6)	0.027
Outcomes (%)			
Need of ICU	8 (10.3)	26 (27.6)	0.005
Need of no invasive MV	3 (3.9)	1 (1)	0.198
Need of invasive MV	-	13 (13.8)	0.001
Extubation	-	9 (9.6)	-
Discharge from ICU	5 (6.5)	21 (22.3)	-
Hospital discharged	65 (84.4)	71 (75.5)	0.152
Still in the hospital	4 (5.2)	6 (6.4)	0.503
Mortality (%)			
Global mortality	8 (10.3)	17 (18)	0.156
Mortality in:			
Not candidates to ALS	6 (60)	12 (75)	0.420
Candidates to ALS	2 (3)	5 (6.4)	0.337

375

376 PCR, polymerase chain reaction. ADRS, adult distress respiratory syndrome. ICU, intensive care unit.

377 ALS, advanced life support. MV, mechanical ventilation.

378 ¹ Measured in 110 patients.

379 ² Measured in 168 patients.

380 ³ Measured in 86 patients.

381 ⁴ see material and methods for antivirals used in our protocol.

382

383

Figure 1. Differences between tocilizumab group and no-tocilizumab group in terms of ICU admission, need of mechanical ventilation and mortality.

ICU, Unit Care Unit. MV, Mechanical Ventilation.

390 **Table 2. Variables associated with ICU admission and/or death whichever came**
391 **first.**

Variables	No ICU admission and/or death, N=121	ICU admission or death, N=50	P - value
Age >62 years (%)	57 (47)	35 (70)	0.006
Male sex (%)	77 (63.6)	35(70)	0.426
Mean (SD) follow-up, days	12 (8.347)	16.6 (9.858)	0.006
Comorbidities (%)	98 (81)	48 (96)	0.012
Hypertension	49 (40.5)	29 (58)	0.037
Diabetes Mellitus	20 (16.5)	6 (12)	0.453
Heart diseases	17 (14)	16 (32)	0.007
Chronic respiratory disease	11 (9)	9 (18)	0.099
Neoplasia	11(9)	6(12)	0.580
Dyslipemia	8 (6.6)	6 (12)	0.356
Lymphoma	2 (1.7)	5 (10)	0.012
Solid organ transplantation	5 (4)	3 (6)	0.693
Human Immunodeficiency Virus	1(0.8)	-	1
Mean (SD) days from symptoms onset to admission	5.98 (6.124)	4.86 (3.084)	0.223
Initial characteristics (%)			
Fever	112(92.6)	44 (88)	0.337
Dyspnoea	59 (48.8)	21 (42)	0.420
Cough	98 (81)	36 (72)	0.222
Normal chest x-ray at admission	12 (10)	5 (10)	0.987
Need of oxygen therapy at day 1	68 (56.7)	38 (76)	0.018
Positive PCR from nasal swab	105 (86.8)	45 (90)	0.559
Laboratory at admission (%)			
Lymphocytes count ¹ <700 cell/mm ³	36 (29.8)	18 (36)	0.424

C-Reactive protein ² >9 mg/dL	39 (32.5)	20 (41.7)	0.261
C-Reactive protein ² >16 mg/dL	23 (19)	25 (50)	0.0001
Treatments received (%)			
Antiviral agents	118 (97.5)	50 (100)	0.261
Steroids prior ICU admission	44 (36.4)	21 (42)	0.490
Tocilizumab	65 (53.7)	12 (24)	<0.0001
Complications (%)			
Cardiovascular	5 (4)	13 (7.6)	0.012
ARDS in the conventional ward	14 (11.6)	30 (60)	0.0001
Acute Kidney Injury	3 (1.8)	12 (24)	0.0001
Invasive ventilation	-	13 (26)	0.0001
Not candidate to ALS	8 (6.6)	18 (36)	0.0001

392

393 PCR, polymerase chain reaction. ICU, intensive care unit. ADRS, adult distress respiratory syndrome.

394 ALS, advanced life support.

395 ¹ Measured in 110 patients.

396 ² Measured in 168 patients.

397 ³ See material and methods section for antivirals used in our protocol.

398

399 **Table 3. Variables significantly associated with the risk of being admitted in the ICU and/or death**
400 **in the multivariable analysis.**

401

Variables ¹	Adjusted odd ratio (95% CI)	P - value
Lymphoma	16.7 (1.7-157.3)	0.01404
Heart disease	2.9 (0.9-9.4)	0.07405
Need of oxygen at day 1	3.4 (1.1-10.5)	0.03406
ARDS prior to ICU admission	50.7 (10.4-245.7)	0.000407
Not candidate to ALS	3.8 (1.2-11.7)	0.0408
Tocilizumab	0.03 (0.007-0.1)	0.000409

410

411 ARDS, Adult respiratory distress syndrome. ICU, intensive care unit. ALS, advanced life support.

412 ¹ Variables included in the analysis: age > 62 years, chronic respiratory disease, hypertension heart
413 disease, lymphoma, C-reactive protein >16 mg/dL, need of oxygen at day 1, cardiovascular
414 complications, ARDS in the conventional ward, not candidate to ALS, tocilizumab administration,
415 propensity score to receive tocilizumab. Acute kidney injury and invasive ventilation were complications
416 that occurred after being admitted in the ICU, therefore, they were not included for the main outcome
417 analysis since this include the need of being admitted in the ICU.

418